Table 3.
Bone Marrow Characteristics
| IWG | Response | WHO Classification 2016 | Cellularity (%) | Blast (%) | Della Porta MDS Displasia Score | Pp65(%) | Cytogenetics | Somatic mutations | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-Rx | Post-Rx | Pre-Rx | Post-Rx | Pre-Rx | Post-Rx | Pre-Rx | Post-Rx | Pre-Rx | Post-Rx | Pre-Rx | Post-Rx | |||
| Responders | PCyR | MDS/MPN-RS-T | 80 | 80 | 0 | 0 | 15 | 12 | 8 | NA | 46,XX,inv(3)(q21q25)[18]46,XX[2] | 46,XX,inv(3)(q21q25)[20] | JAK2 | NA |
| *HI-P+ | MDS-MLD-RS | 45 | 30 | 0 | 0 | 4 | 4 | 63 | 33 | 46,XX[20] | 46,XX[20] | None | NA | |
| HI-P | T-MDS | 100 | 40 | 0 | 0 | 13 | 11 | 7 | 15 | 46,XY[20] | 46,XY[20] | ASXL1, EZH2, KRAS, TET2 | NA | |
| *HI-E+ | MDS-MLD | 100 | 50 | 0 | 0 | 11 | 0 | 17 | 10 | 46,XY[20] | 46,XY[20] | MDM2 | NA | |
| No Responders | NR | CMML0 | 30 | 65 | 2 | 2 | 11 | 6 | 21 | 30 | 46,XY[20] | 46,XY[20] | None | NA |
| NR | Del5q | 30 | 50 | 2 | 3 | 6 | 6 | 17 | 36 | 47,XY,del(5)(q22q35),+21[20] | 47,XY,del(5)(q22q35),+21[20] | None | NA | |
| NR | MDS-MLD (SM-AHN) | 70 | 70 | 4 | 8 | 10 | 12 | 16 | 63 | 46,XY,der(13)t(13;13)(p12;q14)[18]46,idem,der(22)t(13;22)(q14;p11.2)[2] | 46,XY,der(13)t(13;13)(p12;q14)[18]46,idem,der(22)t(13;22)(q14;p11.2)[2] | TET2, DNMT3A, KRAS | NA | |
| NR | CMML0 | 100 | 95 | 5 | 11 | 12 | 9 | ND | ND | 46,XY[20] | 46,XY[20] | NRAS | NRAS, KRAS | |
| NR | MDS-MLD | 100 | NA | 2 | 3 | 5 | 6 | 22 | 50 | 46,XY[20] | 46,XY[20] | JAK2 | JAK2 | |
| NR | MDS-MLD | NA | 75 | 5 | 3 | 12 | 9 | 55 | 90 | 46,XY[20] | 46,XY[20] | ASXL1, JAK2 | ASXL1, JAK2, KRAS, NPM1, NRAS | |
| NR | CMML1 | 95 | 95 | 4 | 9 | 10 | 12 | 17 | 32 | 46,XY[20] | 46,XY[20] | FLT3 | FLT3 | |
| NR | CMML0 | 65 | 40 | 0 | 1 | 7 | 8 | 45 | 40 | 46,XY[20] | 46,XY,del(3)(q13.2q24)[3]/46,XY[17] | ASXL1 | ASXL1, IDH2 | |
| NR | CMML1 | 95 | 90 | 2 | 2 | 6 | 6 | 0 | 0 | 46,XY[20] | 46,XY[20] | MYD88, NRAS, TET2 | NA | |
| NR | MDS-MLD-RS | 95 | 100 | 3 | 3 | 6 | 11 | 40 | 20 | 46,XY[20] | 46,XY[20] | JAK2, TET2 | NA | |
| NR | CMML1 | 70 | 90 | 2 | 6 | 11 | 17 | 20 | 55 | 47,XX,+8[19]/46,XX[1] | 47,XX,+8[20] | JAK2 TET2 | NA | |
| NR | CMML1 | NA | NA | 1 | 0 | 3 | 3 | 9 | 4 | 46,XY[20] | 46,XY[20] | None | NA | |
| NR | MDS-MLD | NA | NA | 1 | 1 | 8 | 8 | 46 | NA | 46,XY[20] | 46,XY[20] | ASXL1, DNMT3A, JAK2 | NA | |
| NR | Del5q | 65 | 50 | 6 | 14 | 13 | 12 | 26 | 1 | 46,XY,del(5)(q13q33)[12]46,idem,del(12)(p12p13)[4]46,idem,der(12)t(12;22)(p11.2;q11.2),der(22)t(12;22)del(12)(p11.2)[4] | 46,XY,del(5)(q13q33)[5]/46,idem,del(12)(p12p13)[9]/46,idem,der(12)t(12;22)(p11.2;q11.2),der(22)t(12;22)del(12)(p11.2)[6] | JAK2, TP53 | NA | |
| Not | NE | CMML1 | NA | NA | 1 | 0 | NA | NA | NA | NA | 47,XY,+8,del(13)(q12q22)[8]/46,XY[4] | 47,XY,+8,del(13)(q12q22)[20] | JAK2, TET2 | NA |
*
+: ongoing response to therapy on study.
Abbreviations: IWG: International working group; PCyR: partial cytogenetic response; HI-P: Hematological improvement of platelets; HI-E: hematological improvement of erythrocytes; NR: no response; NE: not evaluable; Pre-Rx: before therapy; Post-Rx: after therapy; pp65: phosphorylated p65; MDS: myelodysplastic syndromes; CMML: chronic myelomonocytic leukemia; MDS-MLD: MDS with multilineage dysplasia; MDS/MPN-RS-T: myelodysplastic syndrome/myeloproliferative neoplasm with overlap with ring sideroblasts and thrombocytosis; SM-ANH: systemic mastocytosis with an associated hematological neoplasm; T-MDS: therapy-related myelodysplastic syndrome; NA: not available; ND: not done.